Loading
A phase 1/2 trial of trametinib, anlotinib and tislelizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC is a phase 1/2, interventional study registered as NCT06456138 by Shanghai Chest Hospital, with a registry enrolment figure of 60 participants, started 2024-07-01 and due to reach its primary completion in 2026-06-30. Interventions recorded: Trametinib; Anlotinib; Tislelizumab. Conditions listed: KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor. Primary outcome: RP2D; PFS. Lung eligibility wording from the registry: "According to the 8th edition of the AJCC/UICC TNM staging system for NSCLC, patients with locally advanced (stage III B/III C), metastatic or recurrent (stage IV) NSCLC confirmed by histology or cytology who are unable to undergo surgery and radical concomitant radiochemotherapy and are confirmed to". Sites: China. No results are recorded here; the registry entry is the source.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), BeOne Medicines (formerly BeiGene), Tislelizumab and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.